Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells. The company's products in development include UBX 1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020). In July 2022, the company reported positive results from its Phase 1 study. They also include UBX 1967, a preclinical product targeting ophthalmologic diseases. Both products are senolytic medicines. More information...
According to PR-model, unitybiotechnology.com is ranked 1,803,031st in multilingual Wikipedia, in particular this website is ranked 999,635th in English Wikipedia.
The website is placed before football-fan.de and after huskeralum.com in the BestRef global ranking of the most important sources of Wikipedia.
